BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 25468719)

  • 21. Emerging therapies in mantle cell lymphoma.
    Hanel W; Epperla N
    J Hematol Oncol; 2020 Jun; 13(1):79. PubMed ID: 32552760
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mantle Cell Lymphoma: the Role of Risk-Adapted Therapy and Treatment of Relapsed Disease.
    Tarockoff M; Gonzalez T; Ivanov S; Sandoval-Sus J
    Curr Oncol Rep; 2022 Oct; 24(10):1313-1326. PubMed ID: 35639332
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Successful salvage with high-dose sequential chemotherapy coupled with in vivo purging and autologous stem cell transplantation in 2 patients with primary refractory mantle cell lymphoma presenting in the leukemic phase.
    Oyan B; Koc Y; Kansu E
    Int J Hematol; 2005 Feb; 81(2):155-8. PubMed ID: 15765785
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mantle cell lymphoma: 2015 update on diagnosis, risk-stratification, and clinical management.
    Vose JM
    Am J Hematol; 2015 Aug; 90(8):739-45. PubMed ID: 26103436
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mantle cell lymphoma: Frontline and salvage therapy.
    Romaguera JE
    Curr Hematol Malig Rep; 2008 Oct; 3(4):204-9. PubMed ID: 20425467
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognosis and outcome of stem cell transplantation for mantle cell lymphoma.
    Cheminant M; Robinson S; Ribrag V; Le Gouill S; Suarez F; Delarue R; Hermine O
    Expert Rev Hematol; 2015 Aug; 8(4):493-504. PubMed ID: 26091558
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment strategies in mantle cell lymphoma.
    Maddocks K; Blum KA
    Cancer Treat Res; 2015; 165():251-70. PubMed ID: 25655613
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study.
    Visco C; Di Rocco A; Evangelista A; Quaglia FM; Tisi MC; Morello L; Zilioli VR; Rusconi C; Hohaus S; Sciarra R; Re A; Tecchio C; Chiappella A; Marin-Niebla A; McCulloch R; Gini G; Perrone T; Nassi L; Pennese E; Stefani PM; Cox MC; Bozzoli V; Fabbri A; Polli V; Ferrero S; Celis MIA; Sica A; Petrucci L; Arcaini L; Rule S; Krampera M; Vitolo U; Balzarotti M
    Leukemia; 2021 Mar; 35(3):787-795. PubMed ID: 32782382
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Risk - adapted intensive induction therapy, autologous stem cell transplantation, and rituximab maintenance allow to reach a high 7-year survival rate in patients with mantle cell lymphoma].
    Vorobyev VI; Gemdzhian EG; Dubrovin EI; Nesterova ES; Kaplanov KD; Volodicheva EM; Zherebtsova VA; Kravchenko SK
    Ter Arkh; 2019 Jul; 91(7):41-51. PubMed ID: 32598735
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An update on the role of high-dose therapy with autologous or allogeneic stem cell transplantation in mantle cell lymphoma.
    Jacobsen E; Freedman A
    Curr Opin Oncol; 2004 Mar; 16(2):106-13. PubMed ID: 15075900
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG).
    Weide R; Hess G; Köppler H; Heymanns J; Thomalla J; Aldaoud A; Losem C; Schmitz S; Haak U; Huber C; Unterhalt M; Hiddemann W; Dreyling M;
    Leuk Lymphoma; 2007 Jul; 48(7):1299-306. PubMed ID: 17613757
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Current and emerging therapies in mantle cell lymphoma.
    Brett LK; Williams ME
    Curr Treat Options Oncol; 2013 Jun; 14(2):198-211. PubMed ID: 23512567
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Allogeneic Transplantation and Chimeric Antigen Receptor-Engineered T-Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma.
    Gauthier J; Maloney DG
    Hematol Oncol Clin North Am; 2020 Oct; 34(5):957-970. PubMed ID: 32861289
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hematopoietic cell transplantation for mantle cell lymphoma.
    Yanada M; Yamamoto K
    Int J Hematol; 2022 Mar; 115(3):301-309. PubMed ID: 35092557
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment for patients with relapsed/refractory mantle cell lymphoma: European-based recommendations.
    Dreyling M; Aurer I; Cortelazzo S; Hermine O; Hess G; Jerkeman M; Le Gouill S; Ribrag V; Trněný M; Visco C; Walewski J; Zaja F; Zinzani PL
    Leuk Lymphoma; 2018 Aug; 59(8):1814-1828. PubMed ID: 29172868
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mantle cell lymphoma: 2012 update on diagnosis, risk-stratification, and clinical management.
    Vose JM
    Am J Hematol; 2012 Jun; 87(6):604-9. PubMed ID: 22615102
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study.
    Jermann M; Jost LM; Taverna Ch; Jacky E; Honegger HP; Betticher DC; Egli F; Kroner T; Stahel RA
    Ann Oncol; 2004 Mar; 15(3):511-6. PubMed ID: 14998858
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Outpatient fractionated ifosfamide, carboplatin and etoposide as salvage therapy in relapsed and refractory non-Hodgkin's and Hodgkin's lymphoma.
    Hertzberg MS; Crombie C; Benson W; Taper J; Gottlieb D; Bradstock KF
    Ann Oncol; 2006 May; 17 Suppl 4():iv25-30. PubMed ID: 16702181
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Outcome and prognostic factors in patients with mantle-cell lymphoma relapsing after autologous stem-cell transplantation: a retrospective study of the European Group for Blood and Marrow Transplantation (EBMT).
    Dietrich S; Boumendil A; Finel H; Avivi I; Volin L; Cornelissen J; Jarosinska RJ; Schmid C; Finke J; Stevens WB; Schouten HC; Kaufmann M; Sebban C; Trneny M; Kobbe G; Fornecker LM; Schetelig J; Kanfer E; Heinicke T; Pfreundschuh M; Diez-Martin JL; Bordessoule D; Robinson S; Dreger P
    Ann Oncol; 2014 May; 25(5):1053-8. PubMed ID: 24585719
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory mantle cell lymphoma-a "real world" study.
    Epperla N; Hamadani M; Cashen AF; Ahn KW; Oak E; Kanate AS; Calzada O; Cohen JB; Farmer L; Ghosh N; Tallarico M; Nabhan C; Costa LJ; Kenkre VP; Hari PN; Fenske TS
    Hematol Oncol; 2017 Dec; 35(4):528-535. PubMed ID: 28066928
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.